InsiderTrades.com logo
[Urgent] Starlink Set For The Largest IPO In History?
From Paradigm Press   |   Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
Click here now for the urgent details on this hidden play.
Victor M. Clavelli net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Victor Clavelli Biography and Net Worth

Insider of OptiNose
Victor Clavelli joined Optinose in February 2020 as Chief Commercial Officer for Optinose. Mr. Clavelli had an accomplished 20-year career at Pfizer where he held leadership roles including responsibilities for marketing, sales, and regulatory affairs. Most recently, he served as the North American President for Inflammation and Immunology with responsibility for a portfolio spanning topical, small molecule oral, and biologic agents. Mr. Clavelli earned a Bachelor of Science in Physics from Fairfield University and an MBA from the Stern School of Business at New York University.

What is Victor M. Clavelli's net worth?

The estimated net worth of Victor M. Clavelli is at least $51,973.44 as of March 15th, 2021. Mr. Clavelli owns 108,278 shares of OptiNose stock worth more than $51,973 as of November 23rd. This net worth evaluation does not reflect any other investments that Mr. Clavelli may own. Learn More about Victor M. Clavelli's net worth.

How do I contact Victor M. Clavelli?

The corporate mailing address for Mr. Clavelli and other OptiNose executives is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. OptiNose can also be reached via phone at (267) 364-3500 and via email at [email protected]. Learn More on Victor M. Clavelli's contact information.

Has Victor M. Clavelli been buying or selling shares of OptiNose?

Victor M. Clavelli has not been actively trading shares of OptiNose within the last three months. Most recently, Victor M. Clavelli sold 1,256 shares of the business's stock in a transaction on Thursday, December 16th. The shares were sold at an average price of $1.64, for a transaction totalling $2,059.84. Learn More on Victor M. Clavelli's trading history.

Who are OptiNose's active insiders?

OptiNose's insider roster includes Victor Clavelli (Insider), Keith Goldan (CFO), Ramy Mahmoud (COO), Michael Marino, III (Insider), and Peter Miller (CEO). Learn More on OptiNose's active insiders.

Are insiders buying or selling shares of OptiNose?

In the last year, insiders at the sold shares 11 times. They sold a total of 295,529 shares worth more than $374,251.18. The most recent insider tranaction occured on July, 17th when CAO Anthony J Krick sold 6,845 shares worth more than $7,803.30. Insiders at OptiNose own 2.7% of the company. Learn More about insider trades at OptiNose.

Information on this page was last updated on 7/17/2024.

Victor M. Clavelli Insider Trading History at OptiNose

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2021Sell1,256$1.64$2,059.84View SEC Filing Icon  
3/15/2021Sell5,055$3.92$19,815.60108,278View SEC Filing Icon  
See Full Table

Victor M. Clavelli Buying and Selling Activity at OptiNose

This chart shows Victor M Clavelli's buying and selling at OptiNose by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

OptiNose Company Overview

OptiNose logo
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Read More

Today's Range

Now: $0.48
Low: $0.39
High: $0.48

50 Day Range

MA: $0.69
Low: $0.34
High: $0.91

2 Week Range

Now: $0.48
Low: $0.32
High: $2.10

Volume

1,285,310 shs

Average Volume

771,487 shs

Market Capitalization

$72.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
[Urgent] Starlink Set For The Largest IPO In History?
From Paradigm Press   |   Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
Click here now for the urgent details on this hidden play.